Galectin Beats Q2 Loss Estimates
Galectin Therapeutics (NASDAQ:GALT), a clinical-stage biotech firm focused on liver fibrosis and cancer, reported its second quarter 2025 results on August 14, 2025. The most significant news was a lower-than-expected GAAP loss per share of $0.12 and reduced expenses as Galectin advanced its NAVIGATE trial for belapectin, an investigational therapy for MASH cirrhosis. GAAP net loss per share was ($0.12), outperforming analyst GAAP EPS estimates of ($0.16). This improvement stems largely from lower research and development spending following a key clinical milestone. There was no revenue. Overall, the company tightened costs following the main phase of its flagship trial, maintained enough liquidity for near-term activities, and updated investors on progress toward strategic and regulatory goals.
Source: Analyst estimates for the quarter provided by FactSet.
Galectin Therapeutics is a biotechnology company developing novel therapies that target galectins, which are proteins linked to immune and fibrotic diseases. Its main program is belapectin, an intravenous galectin-3 inhibitor drug candidate being tested as a potential treatment for patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), especially those at risk of esophageal varices, which are dangerous vein enlargements in the esophagus caused by advanced liver disease.
Source Fool.com